Disease · MONDO_0005154

liver disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. liver disorder. Diseases, record MONDO_0005154. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005154

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: liver disorder; Open Targets
Open Targets ID: MONDO_0005154; Open Targets
Other names: Disease, Liver, Diseases, Liver, Dysfunction, Liver, Dysfunctions, Liver, Hepatopathy, LD - Liver disease, LIVER DIS, Liver Diseases, Liver Dysfunction, Liver Dysfunctions, Liver disorder NOS, Liver disorder NOS (disorder), Liver disorder in pregnancy, Liver disorder in pregnancy (disorder), Liver disorder in pregnancy - delivered (disorder), Liver disorder in pregnancy NOS (disorder), Liver disorder in pregnancy unspecified (disorder), Liver disorder in pregnancy, unspecified as to episode of care, Liver disorder in pregnancy, with delivery, Unspecified disorder of liver, [X]Diseases of the liver, [X]Diseases of the liver (disorder), disease of liver, disease of liver [Ambiguous], disease of the liver (disorder), disease or disorder of liver, disorder of liver, disorder of liver (disorder), hepatic disease, hepatic disorder, liver and intrahepatic bile duct disorder, liver disease, liver disease or disorder, liver disorder antepartum, liver disorder in pregnancy - delivered; Open Targets
Disease Ontology: DOID:409; Disease Ontology
MeSH: D008107; MeSH
NCI Thesaurus: C3196; NCI Thesaurus
Highest stage of its drugs: Approval, for 16 of its 81 drugs, from ClinicalTrials.gov, DailyMed, PMDA and TTD; Open Targets

Drugs81

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OMEGA-3 FATTY ACIDS	CHEMBL4298065		Approval	ClinicalTrials.gov	2	2	2	Drugs and targets
MEDIUM-CHAIN TRIGLYCERIDES	CHEMBL4298042		Approval	ClinicalTrials.gov	1	1	0	Drugs and targets
OLIVE OIL	CHEMBL2107910		Approval	ClinicalTrials.gov	1	1	0	Drugs and targets
SOYBEAN OIL	CHEMBL1201485		Approval	ClinicalTrials.gov	1	1	0	Drugs and targets
TENOFOVIR DISOPROXIL FUMARATE	CHEMBL1486	Small molecule	Approval	DailyMed and PMDA	2	0	0	Drugs and targets
ACETYLCYSTEINE	CHEMBL600	Small molecule	Approval	TTD	1	0	0	Drugs and targets
AVATROMBOPAG MALEATE	CHEMBL2105758	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CHOLIC ACID	CHEMBL205596	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CYSTEINE HYDROCHLORIDE	CHEMBL1200630	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ENTECAVIR	CHEMBL5314362	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 81

See all 81 drugs

Targets109

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
INSR	Insulin receptor	5	Insulin receptor agonist	Unknown	https://conductscience.org/library/genes/3643	Drugs and targets
SLC5A2	Sodium/glucose cotransporter 2	5	Sodium/glucose cotransporter 2 inhibitor	Phase 3	https://conductscience.org/library/genes/6524	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	4	Glucagon-like peptide 1 receptor agonist	Phase 2	https://conductscience.org/library/genes/2740	Drugs and targets
ABCC8	Sulfonylurea receptor 1, Kir6.2	3	Sulfonylurea receptor 1, Kir6.2 blocker	Unknown	https://conductscience.org/library/genes/6833	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 1	https://conductscience.org/library/genes/1441	Drugs and targets
DPP4	Dipeptidyl peptidase 4	3	Dipeptidyl peptidase IV inhibitor	Unknown	https://conductscience.org/library/genes/1803	Drugs and targets
KCNJ11	Sulfonylurea receptor 1, Kir6.2	3	Sulfonylurea receptor 1, Kir6.2 blocker	Unknown	https://conductscience.org/library/genes/3767	Drugs and targets
MPL	Thrombopoietin receptor	3	Thrombopoietin receptor agonist	Approval	https://conductscience.org/library/genes/4352	Drugs and targets
OPRK1	Kappa-type opioid receptor	2	Kappa opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist	Approval	https://conductscience.org/library/genes/4986	Drugs and targets
PDE5A	cGMP-specific 3',5'-cyclic phosphodiesterase	2	Phosphodiesterase 5A inhibitor	Phase 3	https://conductscience.org/library/genes/8654	Drugs and targets

1 to 10 of 109

See all 109 targets

Trials32

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00910104	Cholestasis Reversal: Efficacy of IV Fish Oil	Phase 2/3	91	2024-09-19	Parenteral Nutrition Associated Liver Disease, Short Bowel Syndrome, Gastrointestinal Disease	FISH OIL TRIGLYCERIDES	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02370251	Compassionate Use of Omegaven in Children	Phase 2/3	63	2019-11-25	Total Parenteral Nutrition-induced Cholestasis, Cholestasis, Short Bowel Syndrome, Gastroschisis, Intestinal Atresia, Infant, Premature, Diseases, Cholestasis of Parenteral Nutrition	FISH OIL TRIGLYCERIDES	Its record names the disease	ClinicalTrials.gov
NCT04168385	MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study	Phase 2	52	2025-12-08	Cholestatic Liver Disease	MARALIXIBAT	Open Targets' reading of its record	ClinicalTrials.gov
NCT01202253	Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom		50	2012-10-11	Candidiasis	ANIDULAFUNGIN	Its record names the disease	ClinicalTrials.gov
NCT00063232	Treating Nonalcoholic Steatohepatitis (NASH) With Metformin	Phase 2	28	2011-07-20	Hepatitis	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT04020016	Study of Nalbuphine ER in Participants With Hepatic Impairment	Phase 1	28	2026-03-19	Hepatic Impairment	NALBUPHINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02511431	Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir	Phase 2	22	2018-05-24	Hepatitis D	LONAFARNIB, RITONAVIR	Its record names the disease	ClinicalTrials.gov
NCT01379469	Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency	Phase 2	20	2021-10-12	Alpha-1-antitrypsin Deficiency, Liver Cirrhosis	CARBAMAZEPINE	Its record names the disease	ClinicalTrials.gov
NCT03154476	Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study	Phase 3	20	2021-07-28	Cirrhosis, Congenital Heart Disease	SILDENAFIL	Its record names the disease	ClinicalTrials.gov
NCT01307098	Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency	Phase 1/2	9	2018-12-11	Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency	SEBELIPASE ALFA	Its record names the disease	ClinicalTrials.gov

1 to 10 of 32

See all 32 trials

Comparisons in its trials16

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Omegaven vs Intralipid: deaths from any cause	3 of 42	12 of 49	91	NCT00910104	Trial comparisons
Omegaven vs Intralipid: serious adverse events	0 of 42	0 of 49	91	NCT00910104	Trial comparisons
Maralixibat: ALGS vs Maralixibat: PFIC: deaths from any cause	1 of 40	0 of 12	52	NCT04168385	Trial comparisons
Maralixibat: ALGS vs Maralixibat: PFIC: serious adverse events	10 of 40	3 of 12	52	NCT04168385	Trial comparisons
Drug-Carbamazepine (Tegretol XR) vs Drug-Carbamazepine (Tegretol XR) Placebo: deaths from any cause	0 of 13	2 of 7	20	NCT01379469	Trial comparisons
Drug-Carbamazepine (Tegretol XR) vs Drug-Carbamazepine (Tegretol XR) Placebo: serious adverse events	6 of 13	4 of 7	20	NCT01379469	Trial comparisons
Sildenafil vs Placebo: deaths from any cause	0 of 10	0 of 10	20	NCT03154476	Trial comparisons
Sildenafil vs Placebo: serious adverse events	0 of 10	0 of 10	20	NCT03154476	Trial comparisons
VTS-270 at 500 mg/kg vs VTS-270 at 1000 mg/kg: Participants With Reduction in Liver Stiffness (kPa)	0 of 1	0 of 1	2	NCT03887533	Trial comparisons
VTS-270 at 500 mg/kg vs VTS-270 at 1000 mg/kg: Participants With Reduction in Plasma Bile Acid B (5α)	1 of 1	0 of 1	2	NCT03887533	Trial comparisons

1 to 10 of 16

See all 16 comparisons in its trials

Papers from its trials18

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23348766	RESULT	1	PubMed
19661785	RESULT	1	PubMed
19053983	RESULT	1	PubMed
18266997	RESULT	1	PubMed
17850410	RESULT	1	PubMed
17635375	RESULT	1	PubMed
17593061	RESULT	1	PubMed
9346731	RESULT	1	PubMed
8213790	RESULT	1	PubMed
40450350	DERIVED	1	PubMed

1 to 10 of 18

See all 18 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005154

GET https://conductscience.org/api/diseases/v1/MONDO_0005154/drugs?page=2

API reference For AI assistants